Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion

Cancer Research

Volumn 61, Issue 1, 2001, Pages 400-405

  Mazumdar, A ^a   Adam, L ^a   Boyd, D ^a   Kumar, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL MOVEMENT; EPITHELIAL CELLS; HUMANS; NEOPLASM INVASIVENESS; NEUREGULIN-1; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035137150     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER.2/neu oncogene
2. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
3. NDF induces expression of a novel 46 kD protein in estrogen receptor positive breast cancer cells
4. Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells
5. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase
6. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells
7. Serine phosphorylation of paxillin by heregulin-β1: Role of p38 mitogen activated protein kinase
8. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis
9. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer
10. Cathepsin-D, urokinase plasminogen activator and type-I plasminogen activator inhibitor in early breast cancer: An immunohistochemical study of prognostic value and relations to tenascin-C and other factors
11. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues
12. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer
13. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane
14. Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer
15. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry
16. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants
17. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor
18. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas
19. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells
20. Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator
21. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
22. Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components
23. 5-directed cell migration
24. Plasmin and plasminogen activator inhibitor type-1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
25. The urokinase-type plasminogen activator system in cancer metastasis: A review
26. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines
27. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
28. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
29. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors
30. Prevention of metastasis by inhibition of the urokinase receptor
31. Induction of a secondary body axis in xenopus by antibodies to β-catenin
32. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. requirement if an upstream motif (- 152/-135) bound with Sp1
33. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor
34. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1dependent and -independent signaling modules
35. Identification of a dual specificity kinase that activates the Jun kinases and p38 MAPK2
36. 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for Ras-activation in CHO cells
37. CD28 mediates a potent costimulatory signal for rapid degradation of Iκ-β which is associated with accelerated activation of various NF-κB/Rel heterodimers
38. Modulation of urokinase plasminogen activator during the transition from quiescent to proliferative state in normal mouse cells
39. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
40. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signalregulated kinase 1 and 2 which is required for increased cellular motility
41. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro
42. Transcription and posttranscriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549
43. Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells
44. Neu differentiating factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit